FDA ad­comm votes in fa­vor of first drug for ag­i­ta­tion as­so­ci­at­ed with Alzheimer's de­men­tia

A joint meet­ing of two FDA ad­comms on Fri­day vot­ed 9-1 in fa­vor of Ot­su­ka and Lund­beck’s drug Rex­ul­ti (br­ex­pipra­zole) for ag­i­ta­tion as­so­ci­at­ed with Alzheimer’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER